Breaking:

MD Anderson - MD Anderson Cancer Center | BioNews Texas

Sort posts

MD Anderson Honors First Winners of the R. Lee Clark Fellow Award

MD Anderson Honors First Winners of the R. Lee Clark Fellow Award

Sixteen junior faculty members of the UT MD Anderson Cancer Center have been honored with the first R. Lee Clark Fellow award. “All of us at MD Anderson would like to congratulate and thank these outstanding individuals for their hard work and dedication to our mission to end the suffering and human loss caused by cancer,” said MD Anderson Provost and ...

Read More »

Fiber-Optic Microscope Will Help Physicians Detect Cancer and Other Diseases at Early Stages

Fiber-Optic Microscope Will Help Physicians Detect Cancer and Other Diseases at Early Stages

Engineering researcher Timothy Muldoon at the University of Arkansas has developed an inexpensive, endoscopic microscope (a tool or technique that obtains histological images from inside the human body in real-time) that is capable of producing high-resolution, sub-cellular images of tissue in real time. Portable, re-usable and easily packaged with conventional endoscopes, the fiber-optic device will help clinicians detect and diagnose early-stage disease, ...

Read More »

MD Anderson Sponsoring Free Oral Cancer Exams At The Texas Medical Center

MD Anderson Sponsoring Free Oral Cancer Exams At The Texas Medical Center

On Friday, April 25, 200 free oral cancer screening exams will be offered to the public in the Duncan Building at the Texas Medical Center. The free, public program is being provided by The University of Texas MD Anderson Cancer Center, and will take place from 10 a.m. to 3 p.m, where doctors will examine people’s mouths. The goal is ...

Read More »

CDK4/6 Inhibitor Palbociclib Shows Promise In Slowing Breast Cancer Progress

CDK4/6 Inhibitor Palbociclib Shows Promise In Slowing Breast Cancer Progress

Research efforts to develop novel treatment options for breast cancer took another step forward recently with the announcement of new Phase II clinical trials for Pfizer’s novel Cyclin Dependent Kinase 4/6 (CDK4/6) inhibitor, Palbociclib, which was announced at this year’s American Association for Cancer Research conference. The results for the clinical trial PALOMA-1 were reported by Dr. Richard S. Finn, ...

Read More »

MD Anderson Research Team Reveals: Tumor-suppressor connects with histone protein to hinder gene expression

MD Anderson Research Team Reveals: Tumor-suppressor connects with histone protein to hinder gene expression

A group of researchers at The University of Texas MD Anderson Cancer Center have discovered a tumor-suppressing protein that acts as a “dimmer switch to tone down gene expression,” according to the lead researcher on the project. This protein accomplishes this dimming effect through a complex mechanism wherein it reads a kind of chemical message attached to another protein that ...

Read More »

MD Anderson Professor’s Research Shows Exercise Benefits All Cancer Survivors Equally, Regardless of Weight

MD Anderson Professor’s Research Shows Exercise Benefits All Cancer Survivors Equally, Regardless of Weight

A new study, led by a professor at MD Anderson, reveales that a simple home exercise regimen offers the same health benefits to survivors of cancer, regardless of their body mass index (BMI). Karen Basen-Engquist, Ph.D., a professor of Behavioral Science at MD Anderson led a team of scientists in conducting an examination of a longitudinal study on the dissimilarities ...

Read More »

MD Anderson researchers selected for inaugural SU2C Phillip A. Sharp Innovation in Collaboration Awards

MD Anderson researchers selected for inaugural SU2C Phillip A. Sharp Innovation in Collaboration Awards

Two SU2C-CRI Immunology Dream Team researchers from the University of Texas MD Anderson Cancer Center were selected during a press event today at the American Association for Cancer Research Annual Meeting 2014,  for the inaugural Stand Up To Cancer (SU2C) Phillip A. Sharp Innovation in Collaboration Awards. James P. Allison, leader of the SU2C-CRI Immunology Dream Team and Padmanee Sharma, ...

Read More »

MD Anderson Research Leads To New Genomic Re-Classification of Lower-Grade Brain Tumors

MD Anderson Research Leads To New Genomic Re-Classification of Lower-Grade Brain Tumors

Researchers report a comprehensive genomic analysis of low-grade brain tumors.  The tumors have been categorized into three groups, one of which has the molecular signature and shortened survival of glioblastoma multiforme, the most lethal form of brain tumor. According to Roel Verhaak, Ph.D., lead author and assistant professor of Bioinformatics and Computational Biology at The University of Texas MD Anderson ...

Read More »

MD Anderson Announces Immunotherapy Collaboration with GSK

MD Anderson Announces Immunotherapy Collaboration with GSK

The University of Texas MD Anderson Cancer Center has formed a research alliance with global leader in pharmaceutical development, GlaxoSmithKline (GSK), to strengthen its efforts in advancing therapies that train the body’s immune system to combat cancer. The collaboration, announced yesterday by the university, completes an ambitious plan, part of MD Anderson’s Moon Shots Program, to partner with leading pharmaceutical companies to more ...

Read More »

Neratinib Breast Cancer Drug Graduates from I-SPY 2, Considered for I-SPY 3 with HER2+ Patients

Neratinib Breast Cancer Drug Graduates from I-SPY 2, Considered for I-SPY 3 with HER2+ Patients

The I-SPY 2 Trial launched by the Foundation for the National Institutes of Health’s Biomarkers Consortium began as a randomized phase II clinical trial for triple negative breast cancer treatment, progressed to “graduate” the drugs veliparib (AbbVie Inc.) and neratinib (Puma Biotechnology), and is now ready to morph into I-SPY 3. The new phase III trial is still being planned, ...

Read More »

AML, High Risk MDS Therapy Quizartinib From Ambit In New MD Anderson-Sponsored Phase 2 Cohort

AML, High Risk MDS Therapy Quizartinib From Ambit In New MD Anderson-Sponsored Phase 2 Cohort

Ambit Biosciences (AMBI) is a biopharmaceutical company that focuses on discovery and development of drugs targeting on autoimmunity and inflammatory disease, has announced the initiation of a Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase1/2 study of quizartinib (AC220) in combination with either 5-azacitidine or low dose cytarabine for previously untreated FMS-like tyrosine kinase 3 internal tandem duplication ...

Read More »

Results From MD Anderson-Sponsored Trial of Sunesis ‘s AML and High-Risk MDS Treatment Vosaroxin to be Presented at AACR 2014

Results From MD Anderson-Sponsored Trial of Sunesis ‘s AML and High-Risk MDS Treatment Vosaroxin to be Presented at AACR 2014

San Francisco-based Sunesis Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, recently announced that it will present updated data from the ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid ...

Read More »

Cancer Cells Forced to Self-Cannibalize in MD Anderson Lab Experiment

Cancer Cells Forced to Self-Cannibalize in MD Anderson Lab Experiment

Anil Sood, MD, at the University of Texas MD Anderson Cancer Center is forcing cancer to take a taste of its own medicine. Cancer cells are known to go through partial autophagy–a process of self-eating–due to stress from chemotherapy or radiation treatment, and enter a sort of slumber that allows them to avoid death. Autophagy is a natural cell process ...

Read More »

MD Anderson’s Freireich and Allison Elected Fellows of the AACR Academy

MD Anderson’s Freireich and Allison Elected Fellows of the AACR Academy

  Emil J. Freireich, a physician who pioneered the use of drug combinations to treat cancer (reversing the bleak survival prospects of children with leukemia), and Jim Allison, a basic scientist who found a new way to treat cancer with the immune system, both members of the University of Texas MD Anderson Cancer Center, have been elected fellows of the ...

Read More »

MD Anderson, CISCRP and KBC Host the First AWARE for All Event in Houston

MD Anderson, CISCRP and KBC Host the First AWARE for All Event in Houston

On May, 9th, the Center for Information and Study on Clinical Research Participation (CISCRP) in collaboration with MD Anderson at the Windsor Village Kingdom Builders’ Center (KBC) will host a free event, the AWARE for All event, to promote understanding and dialogue around cancer clinical research participation in Houston. “In cancer care, clinical trials can offer viable treatment options for patients. The goal of the AWARE for ...

Read More »

MD Anderson chairs James P. Allison and Guillermina Lozano, adjunct Scott M. Lippman elected to AACR board of directors

MD Anderson chairs James P. Allison and Guillermina Lozano, adjunct Scott M. Lippman elected to AACR board of directors

University of Texas MD Anderson chairs James P. Allison and Guillermina Lozano are two of the new five members of the American Association for Cancer Research (AACR) board of directors for the 2014-2017 term. James P. Allison is the university chair of the department of immunology, associate director of the Center for Cancer Immunology Research and the deputy director of the David H. ...

Read More »

MD Anderson’s James. P. Allison Earns Canada Gairdner Award For Cancer Immunotherapy Breakthrough

MD Anderson’s James. P. Allison Earns Canada Gairdner Award For Cancer Immunotherapy Breakthrough

The University of Texas MD Anderson Cancer Center’s Dr. James Allison has been presented with a litany of awards for his pioneering work on cancer immunotherapy during his relatively brief but meteoric presence at the Center. Now, Allison has been granted yet another prestigious award, this time from a leading Canadian institution. The Gairdner Foundation, which through its annual Canada Gairdner ...

Read More »

Ellis Fischel Cancer Center Gains MD Anderson Affiliation

Ellis Fischel Cancer Center Gains MD Anderson Affiliation

The Ellis Fischel Cancer Center in Columbia, Missouri is now an affiliate of the Houston-based MD Anderson Cancer Network, University of Missouri officials announced on Friday. The network is a program of the University of Texas MD Anderson Cancer Center. Affiliate hospitals have direct access to MD Anderson clinical guidelines and operational practices. Ellis Fischel physicians can now consult directly with ...

Read More »

MD Anderson Cancer Center’s Alkek Tower Wins 2014 ASHE Vista Award for New Construction

MD Anderson Cancer Center’s Alkek Tower Wins 2014 ASHE Vista Award for New Construction

The University of Texas MD Anderson Cancer Center Alkek Hospital expansion has won the 2014 Vista Award for New Construction, promoted by the American Society of Healthcare Engineering (ASHE). The building was constructed by the design-build team of McCarthy Building Companies and HKS to meet the current and future needs of both physicians and patients. “The Alkek Tower houses an ...

Read More »

MD Anderson Researcher Part of Effort To Establish New Clinical Trials Standards

MD Anderson Researcher Part of Effort To Establish New Clinical Trials Standards

The American Society for Clinical Oncology (ASCO)  has laid out new recommendations in an effort to make oncology focused clinical trials more effective.  Raising awareness among the patient population on the necessity of clinical trials and encourage participation in the testing of experimental therapies was addressed as well. ASCO addressed several issues in their new recommendations, which were published recently in ...

Read More »

Trend for More Health Problems in Pediatric Cancer Survivors than Siblings Worsens with Age

Trend for More Health Problems in Pediatric Cancer Survivors than Siblings Worsens with Age

A study from St. Jude Children’s Research Hospital, coauthored by Marilyn Stovall from the University of Texas MD Anderson Cancer Center in Houston, reinforces the need for lifelong surveillance of childhood cancer survivors. Looking at 14,359 adult survivors who had cancer at the age of 20 years or younger between the years 1970 and 1986, St. Jude Researchers found a ...

Read More »

MD Anderson Part of Angiosarcoma Study Revealing Treatment Can Be Too Targeted

MD Anderson Part of Angiosarcoma Study Revealing Treatment Can Be Too Targeted

Cancer research continues to progress toward more targeted approaches that engage the immune system to destroy only cancer cells. There is no better example of this than cancer immunotherapy, an MD Anderson-led cancer treatment breakthrough on the vanguard of medical technology. However, an interesting, new study, which MD Anderson was a part of, reveals that for some types of cancer, ...

Read More »

MD Anderson and MedImmune Join Forces to Advance Cancer Immunotherapy

MD Anderson and MedImmune Join Forces to Advance Cancer Immunotherapy

The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson’s Moon Shots Program to develop therapies that unleash patients’ immune systems to attack their cancers. According to Jim Allison, Ph.D., the executive director of the Moon Shots immunotherapy platform and professor and chair of Immunology at ...

Read More »

MD Anderson Honors Two Champions for Women in Medicine and Research

MD Anderson Honors Two Champions for Women in Medicine and Research

The University of Texas MD Anderson Cancer Center yesterday honored two champions of gender equality in medicine and research, in a ceremony in MD Anderson’s Onstead Auditorium. The 2014 Margaret L. Kripke Legend Award was given to Laurie Glimcher, M.D., the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and provost for medical affairs of Cornell University since ...

Read More »
Scroll To Top